The evidence dilemma in genomic medicine.

An ongoing dilemma in genomic medicine is balancing the need for scientific innovation with appropriate evidence thresholds for moving technology into practice. The current low threshold allows unsubstantiated technologies to enter into practice, with the potential to overwhelm the health system. Alternatively, establishing an excessively high threshold for evidence could slow the integration of genomics into practice and present disincentives for investing in research and development. Also, variable coverage and reimbursement policies can lead to differential access to technology, exacerbating health disparities. There is an urgent need for a collaborative process for appropriate transition of genomic discoveries from research to practice.

[1]  E. Harris,et al.  Preventive Services Task Force ( USPSTF ) Screening for Hereditary Hemochromatosis Systematic Review , 2009 .

[2]  P. Ubel,et al.  Barriers to influenza immunization in a low-income urban population. , 2001, American journal of preventive medicine.

[3]  E. Harris,et al.  Screening for Hereditary Hemochromatosis: A Systematic Review for the U.S. Preventive Services Task Force , 2006, Annals of Internal Medicine.

[4]  Muin J Khoury,et al.  Predictive genetic testing for type 2 diabetes , 2006, BMJ : British Medical Journal.

[5]  L. Green.  Translation 2 Research , 2007 .

[6]  S. Teutsch,et al.  Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors , 2007, Genetics in Medicine.

[7]  Roberta A Pagon,et al.  GeneTests: an online genetic information resource for health care providers. , 2006, Journal of the Medical Library Association : JMLA.

[8]  F. Collins,et al.  Shattuck lecture--medical and societal consequences of the Human Genome Project. , 1999, The New England journal of medicine.

[9]  M. Khoury,et al.  Awareness and use of direct-to-consumer nutrigenomic tests, United States, 2006 , 2007, Genetics in Medicine.

[10]  Henk-Jan Guchelaar,et al.  Translating Pharmacogenomics: Challenges on the Road to the Clinic , 2007, PLoS medicine.

[11]  Eric J Topol,et al.  The genomics gold rush. , 2007, JAMA.

[12]  Muin J Khoury,et al.  What is the clinical utility of genetic testing? , 2006, Genetics in Medicine.

[13]  M. Khoury,et al.  The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? , 2007, Genetics in Medicine.

[14]  S. Tunis,et al.  Coverage options for promising technologies: Medicare's 'coverage with evidence development'. , 2006, Health affairs.

[15]  Prateek Gupta,et al.  Genomics and proteomics in process development: opportunities and challenges. , 2007, Trends in biotechnology.

[16]  G. Wilensky.  Developing a center for comparative effectiveness information. , 2006, Health affairs.

[17]  Stephen B. Johnson,et al.  Central challenges facing the national clinical research enterprise. , 2003, JAMA.

[18]  J. Westfall,et al.  Practice-based research--"Blue Highways" on the NIH roadmap. , 2007, JAMA.

[19]  Carlos Martins,et al.  U.S. Preventive Services Task Force (USPSTF) , 2005 .

[20]  M. Khoury,et al.  Genomic profiling to promote a healthy lifestyle: not ready for prime time , 2003, Nature Genetics.

[21]  Kenneth Wells,et al.  Strategies for academic and clinician engagement in community-participatory partnered research. , 2007, JAMA.

[22]  L. Garrison,et al.  Linking pharmacogenetics-based diagnostics and drugs for personalized medicine. , 2006, Health affairs.

[23]  Jim Evans,et al.  Evidence based medicine meets genomic medicine , 2007, Genetics in Medicine.

[24]  Timothy B. Stockwell,et al.  The Diploid Genome Sequence of an Individual Human , 2007, PLoS biology.

[25]  E. Zerhouni.  The NIH Roadmap , 2003, Science.